Prudence Francis, MD, discusses the SOFT trial, which examined suppression of ovarian function, and the impact it could have on the future treatment of women under 35 with HR+ breast cancer.
Prudence Francis, MD
Advertisement
Articles by Prudence Francis, MD
Advertisement
Latest Updated Articles
Ovarian Suppression for Younger Women With HR+ Breast CancerPublished: February 12th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
